CN105358546B - 用作激酶抑制剂的经取代的四氢咔唑及咔唑甲酰胺化合物 - Google Patents
用作激酶抑制剂的经取代的四氢咔唑及咔唑甲酰胺化合物 Download PDFInfo
- Publication number
- CN105358546B CN105358546B CN201480035611.8A CN201480035611A CN105358546B CN 105358546 B CN105358546 B CN 105358546B CN 201480035611 A CN201480035611 A CN 201480035611A CN 105358546 B CN105358546 B CN 105358546B
- Authority
- CN
- China
- Prior art keywords
- carbazole
- fluoro
- yls
- methyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)(c1ccc2c3c(-c4cccc(N(C(c5cccc(F)c5N5C)=O)C5=O)c4Cl)c(F)cc(C(*)=O)c3[n]c2c1)O Chemical compound CC(C)(c1ccc2c3c(-c4cccc(N(C(c5cccc(F)c5N5C)=O)C5=O)c4Cl)c(F)cc(C(*)=O)c3[n]c2c1)O 0.000 description 29
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 3
- NLJRQGBRVLHFNH-KOCCPEBUSA-N CC(C)([C@@H](CC1)Cc2c1c(C([C@@H](C[C@@H]1C(N)=O)F)c3cccc(N(C(C=C4N5C=CC=C4Cl)=O)C5=O)c3C)c1[nH]2)O Chemical compound CC(C)([C@@H](CC1)Cc2c1c(C([C@@H](C[C@@H]1C(N)=O)F)c3cccc(N(C(C=C4N5C=CC=C4Cl)=O)C5=O)c3C)c1[nH]2)O NLJRQGBRVLHFNH-KOCCPEBUSA-N 0.000 description 1
- CDMVUBNQXOVGNW-HNNXBMFYSA-N CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(c4cccc(Cl)c4N4)=O)C4=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O Chemical compound CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(c4cccc(Cl)c4N4)=O)C4=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O CDMVUBNQXOVGNW-HNNXBMFYSA-N 0.000 description 1
- BPDKIMRMIDJFHS-MOHJPFBDSA-N CC1(C)OB(c2cccc(/N=C(/c(cccc3)c3N3C)\OC3=O)c2Cl)OC1(C)C Chemical compound CC1(C)OB(c2cccc(/N=C(/c(cccc3)c3N3C)\OC3=O)c2Cl)OC1(C)C BPDKIMRMIDJFHS-MOHJPFBDSA-N 0.000 description 1
- CZMQZXMTNFXINO-SQFISAMPSA-N Cc(c(NC(C/C(/SC)=N/C=C)=O)ccc1)c1Br Chemical compound Cc(c(NC(C/C(/SC)=N/C=C)=O)ccc1)c1Br CZMQZXMTNFXINO-SQFISAMPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839141P | 2013-06-25 | 2013-06-25 | |
| US61/839,141 | 2013-06-25 | ||
| PCT/US2014/043978 WO2014210085A1 (en) | 2013-06-25 | 2014-06-25 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105358546A CN105358546A (zh) | 2016-02-24 |
| CN105358546B true CN105358546B (zh) | 2017-10-31 |
Family
ID=51210830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480035611.8A Expired - Fee Related CN105358546B (zh) | 2013-06-25 | 2014-06-25 | 用作激酶抑制剂的经取代的四氢咔唑及咔唑甲酰胺化合物 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9334290B2 (OSRAM) |
| EP (1) | EP3013814B1 (OSRAM) |
| JP (1) | JP6353529B2 (OSRAM) |
| KR (1) | KR102346508B1 (OSRAM) |
| CN (1) | CN105358546B (OSRAM) |
| AR (1) | AR096721A1 (OSRAM) |
| AU (1) | AU2014302548B2 (OSRAM) |
| BR (1) | BR112015030723A8 (OSRAM) |
| CA (1) | CA2916500A1 (OSRAM) |
| CL (1) | CL2015003635A1 (OSRAM) |
| CY (1) | CY1119371T1 (OSRAM) |
| DK (1) | DK3013814T3 (OSRAM) |
| EA (1) | EA026729B1 (OSRAM) |
| ES (1) | ES2636652T3 (OSRAM) |
| HR (1) | HRP20171031T1 (OSRAM) |
| HU (1) | HUE034460T2 (OSRAM) |
| IL (1) | IL243296B (OSRAM) |
| LT (1) | LT3013814T (OSRAM) |
| MA (1) | MA38648B1 (OSRAM) |
| MY (1) | MY176631A (OSRAM) |
| PE (1) | PE20160519A1 (OSRAM) |
| PH (1) | PH12015502630A1 (OSRAM) |
| PL (1) | PL3013814T3 (OSRAM) |
| PT (1) | PT3013814T (OSRAM) |
| RS (1) | RS56371B1 (OSRAM) |
| SI (1) | SI3013814T1 (OSRAM) |
| SM (1) | SMT201700422T1 (OSRAM) |
| TN (1) | TN2015000529A1 (OSRAM) |
| TW (1) | TWI648272B (OSRAM) |
| UY (1) | UY35625A (OSRAM) |
| WO (1) | WO2014210085A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9714234B2 (en) | 2013-06-25 | 2017-07-25 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds |
| DK3461821T3 (da) | 2014-10-24 | 2020-08-17 | Bristol Myers Squibb Co | Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere |
| SG11201703187PA (en) | 2014-10-24 | 2017-05-30 | Bristol Myers Squibb Co | Carbazole derivatives |
| SG10201903621SA (en) | 2014-10-24 | 2019-05-30 | Bristol Myers Squibb Co | Tricyclic atropisomer compounds |
| AU2017290142A1 (en) | 2016-07-01 | 2019-01-17 | Brio Device Llc | Intubation stylet with video feed |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
| EP3558977B1 (en) | 2016-12-20 | 2020-10-28 | Bristol-Myers Squibb Company | Process for preparing tetrahydrocarbazole carboxamide compound |
| EP3789040A4 (en) | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT |
| CN117281803A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| JP2025507390A (ja) * | 2022-02-15 | 2025-03-18 | エフ． ホフマン－ラ ロシュ アーゲー | １，２，３，５，６，７－ヘキサヒドロ－ｓ－インダセン誘導体の調製方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101268048A (zh) * | 2005-09-16 | 2008-09-17 | 瑟瑞耐克斯有限公司 | 咔唑衍生物 |
| WO2011159857A1 (en) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| TN2011000274A1 (en) * | 2008-12-19 | 2012-12-17 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| KR20070119606A (ko) | 2004-11-10 | 2007-12-20 | 씨지아이 파마슈티칼스, 인크. | 특정 이미다조[１,２-ａ]피라진-８-일아민, 그의 제조 방법및 용도 |
| AU2005315319B2 (en) | 2004-12-17 | 2011-07-07 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
| TW200716551A (en) | 2005-03-10 | 2007-05-01 | Cgi Pharmaceuticals Inc | Certain substituted amides, method of making, and method of use thereof |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| ES2390135T3 (es) | 2005-11-22 | 2012-11-06 | Merck Sharp & Dohme Corp. | Compuestos tricíclicos útiles como inhibidores de quinasas |
| SG174810A1 (en) | 2006-09-11 | 2011-10-28 | Matrix Lab Ltd | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
| US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| CA2707491A1 (en) | 2007-12-13 | 2009-06-18 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| JP2011512354A (ja) | 2008-02-14 | 2011-04-21 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経機能障害を検知するための新規の造影剤 |
| GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
| CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| AU2011232058B2 (en) | 2010-03-26 | 2016-09-08 | Merck Patent Gmbh | Benzonaphthyridinamines as autotaxin inhibitors |
| EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| WO2012066442A1 (en) | 2010-11-15 | 2012-05-24 | Pfizer Limited | Inhibitors of hiv replication |
| KR101585753B1 (ko) | 2011-05-17 | 2016-01-14 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
-
2014
- 2014-06-24 TW TW103121681A patent/TWI648272B/zh not_active IP Right Cessation
- 2014-06-24 AR ARP140102388A patent/AR096721A1/es unknown
- 2014-06-24 UY UY0001035625A patent/UY35625A/es unknown
- 2014-06-25 MY MYPI2015704738A patent/MY176631A/en unknown
- 2014-06-25 CA CA2916500A patent/CA2916500A1/en not_active Abandoned
- 2014-06-25 LT LTEP14740094.9T patent/LT3013814T/lt unknown
- 2014-06-25 EP EP14740094.9A patent/EP3013814B1/en active Active
- 2014-06-25 BR BR112015030723A patent/BR112015030723A8/pt not_active Application Discontinuation
- 2014-06-25 PL PL14740094T patent/PL3013814T3/pl unknown
- 2014-06-25 RS RS20170904A patent/RS56371B1/sr unknown
- 2014-06-25 WO PCT/US2014/043978 patent/WO2014210085A1/en not_active Ceased
- 2014-06-25 TN TN2015000529A patent/TN2015000529A1/en unknown
- 2014-06-25 SM SM20170422T patent/SMT201700422T1/it unknown
- 2014-06-25 SI SI201430268T patent/SI3013814T1/sl unknown
- 2014-06-25 HU HUE14740094A patent/HUE034460T2/en unknown
- 2014-06-25 ES ES14740094.9T patent/ES2636652T3/es active Active
- 2014-06-25 EA EA201592287A patent/EA026729B1/ru not_active IP Right Cessation
- 2014-06-25 AU AU2014302548A patent/AU2014302548B2/en not_active Ceased
- 2014-06-25 KR KR1020167001632A patent/KR102346508B1/ko not_active Expired - Fee Related
- 2014-06-25 US US14/314,602 patent/US9334290B2/en active Active
- 2014-06-25 PT PT147400949T patent/PT3013814T/pt unknown
- 2014-06-25 DK DK14740094.9T patent/DK3013814T3/en active
- 2014-06-25 MA MA38648A patent/MA38648B1/fr unknown
- 2014-06-25 PE PE2015002665A patent/PE20160519A1/es active IP Right Grant
- 2014-06-25 HR HRP20171031TT patent/HRP20171031T1/hr unknown
- 2014-06-25 JP JP2016523869A patent/JP6353529B2/ja not_active Expired - Fee Related
- 2014-06-25 CN CN201480035611.8A patent/CN105358546B/zh not_active Expired - Fee Related
-
2015
- 2015-11-26 PH PH12015502630A patent/PH12015502630A1/en unknown
- 2015-12-15 CL CL2015003635A patent/CL2015003635A1/es unknown
- 2015-12-22 IL IL243296A patent/IL243296B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/067,915 patent/US20160194338A1/en not_active Abandoned
-
2017
- 2017-06-16 US US15/625,417 patent/US9850258B2/en active Active
- 2017-09-06 CY CY20171100943T patent/CY1119371T1/el unknown
- 2017-11-10 US US15/809,437 patent/US10106559B2/en active Active
-
2018
- 2018-09-25 US US16/140,750 patent/US10435415B2/en active Active
-
2019
- 2019-08-22 US US16/547,675 patent/US20190382416A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101268048A (zh) * | 2005-09-16 | 2008-09-17 | 瑟瑞耐克斯有限公司 | 咔唑衍生物 |
| TN2011000274A1 (en) * | 2008-12-19 | 2012-12-17 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
| WO2011159857A1 (en) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105358546B (zh) | 用作激酶抑制剂的经取代的四氢咔唑及咔唑甲酰胺化合物 | |
| CN105473573B (zh) | 用作激酶抑制剂的咔唑甲酰胺化合物 | |
| CN107108583B (zh) | 可用作激酶抑制剂的吲哚甲酰胺化合物 | |
| CN103509009A (zh) | 2-取代-5-苯基呋喃类化合物、其制备方法、药物组合物及其用途 | |
| HK1223359B (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171031 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |